sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide , doxorubicin ( adriamycin ) , and prednisone ( cap ) ( 30 patients ) or carmustine ( bcnu ) , doxorubicin , and prednisone ( bap ) ( 35 patients ) .
C0026764
multiple myeloma
C0010583
cyclophosphamide